Business Context and Reporting Period
This Form 8-K filing by CareDx, Inc. (CDNA) reports a corporate governance event dated July 1, 2019. The filing details the appointment of a new director to the Company's Board of Directors.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Cash Retainer: $40,000 for Board service and $5,000 for Science and Technology Committee service.
- Initial Equity Grant: Stock options and restricted stock units (RSUs) each with a grant date fair value of $150,000.
- Annual Equity Grant: Automatic annual grants of stock options and RSUs each with a grant date fair value of $100,000.
Material Changes
The material change reported is the addition of Grace Colón, Ph.D. as a Class I director, effective July 1, 2019. Dr. Colón will serve on the Science and Technology Committee. No changes to financial operations or capital structure are reported in this document.
Outlook, Risks, and Management Commentary
Management commentary is limited to the background of the new director, highlighting her experience as CEO of InCarda Therapeutics, Executive Chairman of ProterixBio, and prior roles at Gilead Sciences and Affymetrix. The filing notes the execution of a standard indemnification agreement. No specific risks, contingencies, or forward-looking guidance regarding business operations are provided in this report.
Investor Verification Checklist
- Verify the vesting schedule details for the initial $150,000 equity grants (monthly over three years for options; annual installments for RSUs).
- Confirm the total annual cash compensation obligation for the new director ($45,000).
- Review the press release filed as Exhibit 99.1 for additional context on the appointment.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.